Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.01 BRL | +0.42% | +9.97% | +3.44% |
02-29 | Transcript : Odontoprev S.A., Q4 2023 Earnings Call, Feb 29, 2024 | |
02-28 | Odontoprev S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company appears highly valued given the size of its balance sheet.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.44% | 1.29B | B | ||
-15.51% | 5.6B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ODPV3 Stock
- Ratings Odontoprev S.A.